Intellia Therapeutics
NTLA
304 hedge funds and large institutions have $1.41B invested in Intellia Therapeutics in 2026 Q1 according to their latest regulatory filings, with 63 funds opening new positions, 127 increasing their positions, 63 reducing their positions, and 46 closing their positions.
164% more call options, than puts
Call options by funds: $60.6M | Put options by funds: $23M
102% more repeat investments, than reductions
Existing positions increased: 127 | Existing positions reduced: 63
51% more capital invested
Capital invested by funds: $938M → $1.41B (+$476M)
37% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 46
4% more funds holding
Funds holding: 292 → 304 (+12)
3.54% more ownership
Funds ownership: 89.95% → 93.49% (+3.5%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$25.6M |
| 2 |
BlackRock
New York
|
+$23.9M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$23.3M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$17.8M |
| 5 |
CGH
Contrarius Group Holdings
Hamilton,
Bermuda
|
+$15.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$15M |
| 2 |
AC
Armistice Capital
New York
|
-$10.4M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$6.27M |
| 4 |
Barclays
London,
United Kingdom
|
-$4.64M |
| 5 |
HF
HRT Financial
New York
|
-$3.34M |
NTLA Hedge Fund Activity: Q1 2026 in Review
304 institutional investors reported a position in Intellia Therapeutics (NTLA) for Q1 2026, worth a combined $1.41B — up 51% from $938M a quarter earlier.
Buyers outnumbered sellers: 63 funds opened new NTLA positions and 46 closed out — a net gain of 17 holders — while 127 added to existing stakes and 63 trimmed.
The largest buyer was Two Sigma Investments, adding an estimated $25.6M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $15M sold.
- 304 institutional investors held Intellia Therapeutics (NTLA) as of Q1 2026, up from 292 in Q4 2025.
- Funds reported $1.41B of Intellia Therapeutics stock for Q1 2026, up 51% quarter-over-quarter.
- 63 funds opened new Intellia Therapeutics positions in Q1 2026 and 46 closed out, a net change of +17 holders.
- The largest Intellia Therapeutics buyer in Q1 2026 was Two Sigma Investments, an estimated $25.6M added.
- The largest Intellia Therapeutics seller in Q1 2026 was Renaissance Technologies, an estimated $15M sold.
Based on aggregated 13F filings for Q1 2026.